CYP2C19 gene product metabolic activity interpretation in Blood or Tissue Qualitative by Molecular genetics method

CYP2C19 gene prod met act imp Bld/T-Imp

Definition

The CYP2C19 gene product metabolic activity interpretation is determined by the reporting lab and returned with the structured test results. The Preferred Answer list associated with this term is based on the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for reporting CYP2C19 gene product metabolic activity (phenotype), which apply to both genetic and enzymatic assays (this LOINC term represents a genetic assay). This specific interpretation would be considered a separate observation made by the lab in addition to the primary reported results (e.g., genotype or measured activity level) and it could be included with other assay-specific observations, which would ideally support the interpretation value. [https://cpicpgx.org/resources.html]

Activ; Actvty; Blood; CPCJ; CYP2C; CYP2C19 gene prod met act imp; CYPIIC17; CYPIIC19; cytochrome P-450 II C; cytochrome P450, family 2, subfamily C, polypeptide 19; Drug metabolism; Gene prod met act imp; Impression; Impression/interpretation of study; Impressions; Interp; Interpret; Interpretation; Interpt; Intrp; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.PHARMG; Movements; Ordinal; P450C2C; P450IIC19; PCR; Phenotype; Point in time; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue

1 further terms